Treatment for Dyspareunia in postmenopausal Women

This postmenopausal woman is experiencing dyspareunia due to atrophic vaginitis caused by a lack of estrogen. While topical or systemic hormone replacement therapy can be effective treatments, this patient specifically doesn’t want hormonal treatment. In this case, the best option is Sylk moisturizer, one of two non-hormonal preparations available for vaginal atrophy. Replens is the other option.

It’s important to note that KY jelly is a lubricant only and doesn’t come with an applicator. Sylk and Replens are classified as vaginal moisturizers, which can be applied every few days and provide long-lasting relief, including relief of itching. KY jelly, on the other hand, is only effective until the water evaporates, which is typically within an hour.

In summary, for postmenopausal women experiencing dyspareunia due to atrophic vaginitis, non-hormonal vaginal moisturizers like Sylk and Replens can be effective treatments.

First-Line Treatment for Menorrhagia

When it comes to treating menorrhagia, the levonorgestrel-releasing intrauterine system (LNG-IUS) is considered the first-line option by NICE. This is especially true for women with no identified pathology, fibroids less than 3 cm in diameter, or suspected or diagnosed adenomyosis. While the combined oral contraceptive pill is also an option, it is not the preferred choice.

It is important to note that a repeat ultrasound may not be the next step in management, as the history of menorrhagia is the crucial point to consider. If menorrhagia is not present, the treatment plan may differ. Ulipristal acetate may be used for larger fibroids, but it is typically started in secondary care. Referral for surgical treatment should not be the first-line option, as more conservative measures should be tried initially.

Patients with bacterial vaginosis who have a history of clue cells can be treated with topical clindamycin as an alternative to metronidazole, according to the BNF. This is particularly useful for patients who are allergic to metronidazole.

Bacterial vaginosis (BV) is a condition where there is an overgrowth of anaerobic organisms, particularly Gardnerella vaginalis, in the vagina. This leads to a decrease in the amount of lactobacilli, which produce lactic acid, resulting in an increase in vaginal pH. BV is not a sexually transmitted infection, but it is commonly seen in sexually active women. Symptoms include a fishy-smelling vaginal discharge, although some women may not experience any symptoms at all. Diagnosis is made using Amsel’s criteria, which includes the presence of thin, white discharge, clue cells on microscopy, a vaginal pH greater than 4.5, and a positive whiff test. Treatment involves oral metronidazole for 5-7 days, with a cure rate of 70-80%. However, relapse rates are high, with over 50% of women experiencing a recurrence within 3 months. Topical metronidazole or clindamycin may be used as alternatives.

Bacterial vaginosis during pregnancy can increase the risk of preterm labor, low birth weight, chorioamnionitis, and late miscarriage. It was previously recommended to avoid oral metronidazole in the first trimester and use topical clindamycin instead. However, recent guidelines suggest that oral metronidazole can be used throughout pregnancy. The British National Formulary (BNF) still advises against using high-dose metronidazole regimens. Clue cells, which are vaginal epithelial cells covered with bacteria, can be seen on microscopy in women with BV.

Cervical screening is only available to women between the ages of 25 and 64, and cannot be offered to those outside of this age range. However, if a patient has never had a screening test or has not had one since age 50, they can have a one-off test. Unlike breast and bowel screening, patients cannot self-refer for cervical screening outside of the routine age range. This is because cervical cancer is unlikely to develop after this age if previous tests have been normal. Patients with symptoms of cervical cancer should be referred for colposcopy, while asymptomatic patients should not be referred as screening is designed to detect asymptomatic cases.

Understanding Cervical Cancer Screening in the UK

Cervical cancer screening is a well-established program in the UK that aims to detect Premalignant changes in the cervix. This program is estimated to prevent 1,000-4,000 deaths per year. However, it should be noted that cervical adenocarcinomas, which account for around 15% of cases, are frequently undetected by screening.

The screening program has evolved significantly in recent years. Initially, smears were examined for signs of dyskaryosis, which may indicate cervical intraepithelial neoplasia. However, the introduction of HPV testing allowed for further risk stratification. Patients with mild dyskaryosis who were HPV negative could be treated as having normal results. The NHS has now moved to an HPV first system, where a sample is tested for high-risk strains of human papillomavirus (hrHPV) first, and cytological examination is only performed if this is positive.

All women between the ages of 25-64 years are offered a smear test. Women aged 25-49 years are screened every three years, while those aged 50-64 years are screened every five years. Cervical screening cannot be offered to women over 64, unlike breast screening, where patients can self-refer once past screening age. In Scotland, screening is offered from 25-64 every five years.

In special situations, cervical screening in pregnancy is usually delayed until three months postpartum, unless there has been missed screening or previous abnormal smears. Women who have never been sexually active have a very low risk of developing cervical cancer and may wish to opt-out of screening.

While there is limited evidence to support it, the current advice given out by the NHS is that the best time to take a cervical smear is around mid-cycle. Understanding the cervical cancer screening program in the UK is crucial for women to take control of their health and prevent cervical cancer.

For women over 40, it is recommended to consider a COC pill containing less than 30 µg ethinylestradiol as the first-line option due to the potentially lower risks of VTE, cardiovascular disease, and stroke compared to formulations with higher doses of estrogen. COCP can also help reduce menstrual bleeding and pain, which may be beneficial for women in this age group. However, it is important to consider special considerations when prescribing COCP to women over 40.

Levonorgestrel or norethisterone-containing COCP preparations should be considered as the first-line option for women over 40 due to the potentially lower risk of VTE compared to formulations containing other progestogens. The UKMEC criteria for women over 40 is 2, while for women from menarche until 40, it is 1. The faculty of sexual and reproductive health recommends the use of COCP until age 50 if there are no other contraindications. Women aged 50 and over should be advised to use an alternative, safer method for contraception.

Extended or continuous COCP regimens can be offered to women for contraception and to control menstrual or menopausal symptoms. COCP is associated with a reduced risk of ovarian and endometrial cancer that lasts for several decades after cessation. It may also help maintain bone mineral density compared to non-use of hormones in the perimenopause.

Although meta-analyses have found a slightly increased risk of breast cancer among women using COCP, there is no significant risk of breast cancer ten years after cessation. Women who smoke should be advised to stop COCP at 35 as this is the age at which excess risk of mortality associated with smoking becomes clinically significant.

Women over the age of 40 still require effective contraception until they reach menopause, despite a significant decline in fertility. The Faculty of Sexual and Reproductive Healthcare (FSRH) has produced specific guidance for this age group, titled Contraception for Women Aged Over 40 Years. No method of contraception is contraindicated by age alone, with all methods being UKMEC1 except for the combined oral contraceptive pill (UKMEC2 for women >= 40 years) and Depo-Provera (UKMEC2 for women > 45 years). The FSRH guidance provides specific considerations for each method, such as the use of COCP in the perimenopausal period to maintain bone mineral density and reduce menopausal symptoms. Depo-Provera use is associated with a small loss in bone mineral density, which is usually recovered after discontinuation. The FSRH also provides a table detailing how different methods may be stopped based on age and amenorrhea status. Hormone replacement therapy cannot be relied upon for contraception, and a separate method is needed. The FSRH advises that the POP may be used in conjunction with HRT as long as the HRT has a progestogen component, while the IUS is licensed to provide the progestogen component of HRT.

Managing Heavy Menstrual Bleeding

Heavy menstrual bleeding, also known as menorrhagia, is a condition where a woman experiences excessive blood loss during her menstrual cycle. While it was previously defined as total blood loss of more than 80 ml per cycle, the management of menorrhagia now depends on the woman’s perception of what is excessive. Prior to the 1990s, hysterectomy was a common treatment for heavy periods, but the approach has since shifted.

To manage menorrhagia, a full blood count should be performed in all women, and a routine transvaginal ultrasound scan should be arranged if symptoms suggest a structural or histological abnormality. If contraception is not required, mefenamic acid or tranexamic acid can be used. If there is no improvement, other drugs can be tried while awaiting referral.

For women who require contraception, options include the intrauterine system (Mirena), combined oral contraceptive pill, and long-acting progestogens. Norethisterone can also be used as a short-term option to rapidly stop heavy menstrual bleeding. A flowchart can be used to guide the management of menorrhagia.

Management of Suspicious Bleeding in a High-Risk Patient

This patient has several risk factors for endometrial dysplasia and cancer, including obesity, polycystic ovarian syndrome, and long-term amenorrhea. Recently, she has experienced a change in her bleeding pattern from amenorrhea to spotting, which requires ruling out any suspicious causes. According to NICE guidelines, women aged 55 years and over with postmenopausal bleeding should be referred for an appointment within 2 weeks for endometrial cancer. For women under 55 years, a suspected cancer pathway referral should be considered. A direct access ultrasound scan may also be considered for women aged 55 years and over with unexplained symptoms of vaginal discharge, thrombocytosis, haematuria, low haemoglobin levels, thrombocytosis, or high blood glucose levels.

In this case, checking a day 21 progesterone is not useful as the patient is amenorrheic. The FSH:LH ratio may be helpful in diagnosing polycystic ovarian syndrome, but it will not guide management in this case. The use of a coil may be considered after a TVUS to measure endometrial thickness if the patient is deemed low risk. Overall, it is important to promptly investigate any suspicious bleeding in high-risk patients to ensure early detection and management of any potential malignancies.

Elevated Ca125 and Normal Examination: What to Do Next?

This patient has an elevated Ca125 but a normal examination. Although the elevated result was detected during screening, she admits to experiencing bloating, which can be an early symptom of ovarian cancer. However, it’s important to note that Ca125 can be elevated for non-malignancy reasons, and if the ovarian cancer is not epithelial in origin, the Ca125 can be normal.

According to NICE guidelines, if a woman has symptoms that suggest ovarian cancer, serum CA125 should be measured in primary care. If the serum CA125 is 35 IU/ml or greater, an ultrasound scan of the abdomen and pelvis should be arranged. If the ultrasound suggests ovarian cancer, the woman should be referred urgently for further investigation.

If a woman has a normal serum CA125 (less than 35 IU/ml) or a CA125 of 35 IU/ml or greater but a normal ultrasound, she should be assessed carefully for other clinical causes of her symptoms and investigated if appropriate. If no other clinical cause is apparent, she should be advised to return to her GP if her symptoms become more frequent and/or persistent.

To alleviate vaginal symptoms, vaginal topical oestrogen can be used alongside HRT. Compared to systemic treatment, low-dose vaginal topical oestrogen is more effective in providing relief for vaginal symptoms. Patients should be reviewed after 3 months of treatment. It is recommended to consider stopping treatment at least once a year, but in some cases, long-term treatment may be necessary for persistent symptoms. If symptoms persist, increasing the dose or seeking specialist referral may be necessary. Testosterone supplementation is only recommended for sexual dysfunction and should be initiated after consulting a specialist. Sildenafil is not effective in treating menopausal symptoms.

Managing Menopause: Lifestyle Modifications, HRT, and Non-HRT Options

Menopause is a natural biological process that marks the end of a woman’s reproductive years. It is diagnosed when a woman has not had a period for 12 months. Menopausal symptoms are common and can last for several years. The management of menopause can be divided into three categories: lifestyle modifications, hormone replacement therapy (HRT), and non-hormone replacement therapy.

Lifestyle modifications can help manage symptoms such as hot flashes, sleep disturbance, mood changes, and cognitive symptoms. Regular exercise, weight loss, stress reduction, and good sleep hygiene are recommended.

HRT is an effective treatment for menopausal symptoms, but it is not suitable for everyone. Women with current or past breast cancer, any oestrogen-sensitive cancer, undiagnosed vaginal bleeding, or untreated endometrial hyperplasia should not take HRT. HRT brings certain risks, including an increased risk of venous thromboembolism, stroke, coronary heart disease, breast cancer, and ovarian cancer.

Non-HRT options include fluoxetine, citalopram, or venlafaxine for vasomotor symptoms, vaginal lubricants or moisturisers for vaginal dryness, self-help groups, cognitive behaviour therapy, or antidepressants for psychological symptoms, and vaginal oestrogen for urogenital symptoms.

When stopping HRT, it is important to gradually reduce the dosage to limit recurrence in the short term. Women should be referred to secondary care if treatment has been ineffective, if there are ongoing side effects, or if there is unexplained bleeding.

The combined oral contraceptive pill (COC) is not recommended for individuals with current gallbladder disease as per the United Kingdom Medical Eligibility Criteria (UKMEC) 3. This is because the risks of using COC outweigh the benefits, as it may increase the risk of gallbladder disease and worsen existing conditions. However, if the patient has undergone cholecystectomy or is asymptomatic, COC may be considered as per UKMEC 2.

The patient’s age is not a factor in determining the suitability of COC in this scenario, as being aged 40 or over is the only age-related UKMEC 3.

The patient’s BMI is within an acceptable range for COC use.

Breastfeeding less than six weeks postpartum is not recommended as per UKMEC 4, as it poses an unacceptable risk to health. From two weeks to six months, it is UKMEC 2, and from six months onwards, it is UKMEC 1.

Smoking ten cigarettes per day is only a UKMEC 3 if the patient is over 35 years of age.

Contraindications for Combined Oral Contraceptive Pill

The decision to prescribe the combined oral contraceptive pill is based on the UK Medical Eligibility Criteria (UKMEC), which categorizes potential cautions and contraindications on a four-point scale. UKMEC 1 represents a condition for which there is no restriction for the use of the contraceptive method, while UKMEC 4 represents an unacceptable health risk. Examples of UKMEC 3 conditions include controlled hypertension, immobility, and a family history of thromboembolic disease in first-degree relatives under 45 years old. Examples of UKMEC 4 conditions include a history of thromboembolic disease or thrombogenic mutation, breast cancer, and uncontrolled hypertension.

In 2016, the UKMEC was updated to reflect that breastfeeding between 6 weeks and 6 months postpartum is now classified as UKMEC 2 instead of UKMEC 3. Diabetes mellitus diagnosed over 20 years ago is classified as UKMEC 3 or 4 depending on severity. It is important for healthcare providers to consider these contraindications when deciding whether to prescribe the combined oral contraceptive pill to their patients.

No additional contraception is needed if an LNG-IUS or Levonorgestrel-IUS is inserted on day 1-7 of the cycle. However, if it is inserted outside this timeframe, 7 days of additional contraception is required. Since the patient is currently on day 6 of her cycle, there is no need for extra precautions.

New intrauterine contraceptive devices include the Jaydess® IUS and Kyleena® IUS. The Jaydess® IUS is licensed for 3 years and has a smaller frame, narrower inserter tube, and less levonorgestrel than the Mirena® coil. The Kyleena® IUS has 19.5mg LNG, is smaller than the Mirena®, and is licensed for 5 years. Both result in lower serum levels of LNG, but the rate of amenorrhoea is less with Kyleena® compared to Mirena®.

The appropriate HRT regimen for this patient is a transdermal cyclical one, as she has had a period within the last year. As she has an intact uterus, a combined regimen with both oestrogen and progesterone is necessary. Given her increased risk of venous thromboembolism and cardiovascular disease due to obesity, transdermal preparations are recommended over oral options. Low-dose vaginal oestrogen is not sufficient for her systemic symptoms. An oestrogen-only preparation is not appropriate for women with a uterus. A transdermal continuous combined regimen is not recommended within 12 months of the last menstrual period. If the patient cannot tolerate the transdermal option, an oral cyclical regimen may be considered.

Managing Menopause: Lifestyle Modifications, HRT, and Non-HRT Options

Menopause is a natural biological process that marks the end of a woman’s reproductive years. It is diagnosed when a woman has not had a period for 12 months. Menopausal symptoms are common and can last for several years. The management of menopause can be divided into three categories: lifestyle modifications, hormone replacement therapy (HRT), and non-hormone replacement therapy.

Lifestyle modifications can help manage symptoms such as hot flashes, sleep disturbance, mood changes, and cognitive symptoms. Regular exercise, weight loss, stress reduction, and good sleep hygiene are recommended.

HRT is an effective treatment for menopausal symptoms, but it is not suitable for everyone. Women with current or past breast cancer, any oestrogen-sensitive cancer, undiagnosed vaginal bleeding, or untreated endometrial hyperplasia should not take HRT. HRT brings certain risks, including an increased risk of venous thromboembolism, stroke, coronary heart disease, breast cancer, and ovarian cancer.

Non-HRT options include fluoxetine, citalopram, or venlafaxine for vasomotor symptoms, vaginal lubricants or moisturisers for vaginal dryness, self-help groups, cognitive behaviour therapy, or antidepressants for psychological symptoms, and vaginal oestrogen for urogenital symptoms.

When stopping HRT, it is important to gradually reduce the dosage to limit recurrence in the short term. Women should be referred to secondary care if treatment has been ineffective, if there are ongoing side effects, or if there is unexplained bleeding.

Ovarian hyperstimulation syndrome can occur as a result of ovulation induction, as seen in this case with symptoms such as ascites, vomiting, diarrhea, and high hematocrit. Different medications can be used for ovulation induction, with gonadotrophin therapy carrying a higher risk of ovarian hyperstimulation syndrome compared to other options like clomiphene citrate, raloxifene, letrozole, or anastrozole. It is likely that the patient in question was given gonadotrophin therapy.

Understanding Ovulation Induction and Its Categories

Ovulation induction is a common treatment for couples who have difficulty conceiving naturally due to ovulation disorders. The process of ovulation requires a balance of hormones and feedback loops between the hypothalamus, pituitary gland, and ovaries. Anovulation can occur due to alterations in this balance, which can be classified into three categories: hypogonadotropic hypogonadal anovulation, normogonadotropic normoestrogenic anovulation, and hypergonadotropic hypoestrogenic anovulation. The goal of ovulation induction is to induce mono-follicular development and subsequent ovulation, leading to a singleton pregnancy.

There are various forms of ovulation induction, starting with the least invasive and simplest management option first. Exercise and weight loss are typically the first-line treatment for patients with polycystic ovarian syndrome, as ovulation can spontaneously return with even a modest 5% weight loss. Letrozole is now considered the first-line medical therapy for patients with PCOS due to its reduced risk of adverse effects on endometrial and cervical mucous compared to clomiphene citrate. Clomiphene citrate is a selective estrogen receptor modulator that acts primarily at the hypothalamus, blocking the negative feedback effect of estrogens. Gonadotropin therapy tends to be the treatment used mostly for women with hypogonadotropic hypogonadism.

One potential side effect of ovulation induction is ovarian hyperstimulation syndrome (OHSS), which can be life-threatening if not identified and managed promptly. OHSS occurs when ovarian enlargement with multiple cystic spaces form, and an increase in the permeability of capillaries leads to a fluid shift from the intravascular to the extra-vascular space. The severity of OHSS varies, with the risk of severe OHSS occurring in less than 1% of all women undergoing ovarian induction. Management includes fluid and electrolyte replacement, anticoagulation therapy, abdominal ascitic paracentesis, and pregnancy termination to prevent further hormonal imbalances.

Referral to gynaecology is necessary to rule out endometrial cancer due to the patient’s past experience of intermenstrual bleeding.

Endometrial cancer is a type of cancer that is commonly found in women who have gone through menopause, but it can also occur in around 25% of cases before menopause. The prognosis for this type of cancer is usually good due to early detection. There are several risk factors associated with endometrial cancer, including obesity, nulliparity, early menarche, late menopause, unopposed estrogen, diabetes mellitus, tamoxifen, polycystic ovarian syndrome, and hereditary non-polyposis colorectal carcinoma. Symptoms of endometrial cancer include postmenopausal bleeding, which is usually slight and intermittent at first before becoming heavier, and changes in intermenstrual bleeding for premenopausal women. Pain is not common and typically signifies extensive disease, while vaginal discharge is unusual.

When investigating endometrial cancer, women who are 55 years or older and present with postmenopausal bleeding should be referred using the suspected cancer pathway. The first-line investigation is trans-vaginal ultrasound, which has a high negative predictive value for a normal endometrial thickness of less than 4 mm. Hysteroscopy with endometrial biopsy is also commonly used for diagnosis. Treatment for localized disease typically involves total abdominal hysterectomy with bilateral salpingo-oophorectomy, while patients with high-risk disease may require postoperative radiotherapy. Progestogen therapy may be used in frail elderly women who are not considered suitable for surgery. It is important to note that the combined oral contraceptive pill and smoking are protective against endometrial cancer.

Management of Unilateral Spontaneous Bloody Nipple Discharge

When a patient presents with unilateral spontaneous bloody nipple discharge, it is important to rule out breast cancer before assuming it is duct ectasia. Reassuring the patient without proper investigation is inappropriate. Prescribing antibiotics or sending a sample for culture without evidence of cellulitis can delay a diagnosis and is not the correct management. Advising the patient to express the discharge again is also inappropriate.

If a non-lactational abscess is suspected, it is best to refer the patient to the emergency department for proper drainage. However, if infection is less likely, an urgent referral for suspected cancer is appropriate. According to NICE guidelines, patients aged 50 and over with any symptoms in one nipple only, such as discharge, retraction, or other changes of concern, should be referred for an appointment within 2 weeks. However, regardless of age, a patient presenting with unilateral spontaneous bloody discharge should have an urgent referral.

In summary, proper investigation and referral are crucial in managing unilateral spontaneous bloody nipple discharge to ensure timely diagnosis and appropriate management.

The primary objective of cervical screening is to identify pre-cancerous alterations rather than detecting cancer.

Understanding Cervical Cancer Screening in the UK

Cervical cancer screening is a well-established program in the UK that aims to detect Premalignant changes in the cervix. This program is estimated to prevent 1,000-4,000 deaths per year. However, it should be noted that cervical adenocarcinomas, which account for around 15% of cases, are frequently undetected by screening.

The screening program has evolved significantly in recent years. Initially, smears were examined for signs of dyskaryosis, which may indicate cervical intraepithelial neoplasia. However, the introduction of HPV testing allowed for further risk stratification. Patients with mild dyskaryosis who were HPV negative could be treated as having normal results. The NHS has now moved to an HPV first system, where a sample is tested for high-risk strains of human papillomavirus (hrHPV) first, and cytological examination is only performed if this is positive.

All women between the ages of 25-64 years are offered a smear test. Women aged 25-49 years are screened every three years, while those aged 50-64 years are screened every five years. Cervical screening cannot be offered to women over 64, unlike breast screening, where patients can self-refer once past screening age. In Scotland, screening is offered from 25-64 every five years.

In special situations, cervical screening in pregnancy is usually delayed until three months postpartum, unless there has been missed screening or previous abnormal smears. Women who have never been sexually active have a very low risk of developing cervical cancer and may wish to opt-out of screening.

While there is limited evidence to support it, the current advice given out by the NHS is that the best time to take a cervical smear is around mid-cycle. Understanding the cervical cancer screening program in the UK is crucial for women to take control of their health and prevent cervical cancer.

The failure rate of female sterilisation is 1 in 200.

Understanding Female Sterilisation

Female sterilisation is a common method of permanent contraception for women. It has a low failure rate of 1 per 200 and is usually performed by laparoscopy under general anaesthetic. The procedure is generally done as a day case and involves various techniques such as clips (e.g. Filshie clips), blockage, rings (Falope rings) and salpingectomy. However, there are potential complications such as an increased risk of ectopic pregnancy if sterilisation fails, as well as general risks associated with anaesthesia and laparoscopy.

In the event that a woman wishes to reverse the procedure, the current success rate of female sterilisation reversal is between 50-60%. It is important for women to understand the risks and benefits of female sterilisation before making a decision.

Management of Unscheduled Bleeding in a Young Lady on Depo-Provera Injection

This patient is a young lady who has been experiencing unscheduled bleeding after being put on the Depo-Provera injection. However, she has no red flag symptoms and is up-to-date with her cervical smears, which provides reassurance to her history. At this stage, blood tests and a pelvic ultrasound scan are not necessary, but may be considered later on. Referral to a gynaecologist is not indicated as there are no alarming symptoms present.

It is important to follow advice from the cervical screening hub regarding cervical smears and not order one sooner than indicated. If any alarming symptoms arise, referral to a gynaecologist is recommended. For women experiencing unscheduled bleeding while on a progesterone-only injectable and who are medically eligible, a combined oral contraceptive can be offered for three months in the usual cyclic manner. The longer-term use of the combined contraceptive pill with the injectable progesterone is a matter of clinical judgement.

The cause of endometrial hyperplasia is the lack of opposition to oestrogen by progesterone. This condition is linked to various factors such as taking unopposed oestrogen, obesity, late menopause, early menarche, being over 35 years old, smoking, nulliparity, and the use of tamoxifen. Tamoxifen is a risk factor because it has a pro-oestrogen effect on the uterus and bones, but it also has an anti-oestrogen effect on the breast.

Understanding Endometrial Hyperplasia

Endometrial hyperplasia is a condition characterized by the abnormal growth of the endometrium, which is the lining of the uterus. This growth is excessive compared to the normal proliferation that occurs during the menstrual cycle. There are different types of endometrial hyperplasia, including simple, complex, simple atypical, and complex atypical. Patients with this condition may experience abnormal vaginal bleeding, such as intermenstrual bleeding.

The management of endometrial hyperplasia depends on the type and severity of the condition. For simple endometrial hyperplasia without atypia, high dose progestogens may be prescribed, and repeat sampling is done after 3-4 months. The levonorgestrel intra-uterine system may also be used. However, for atypical cases, hysterectomy is usually advised.

In summary, endometrial hyperplasia is a condition that requires proper diagnosis and management to prevent the development of endometrial cancer. Patients experiencing abnormal vaginal bleeding should seek medical attention to determine the underlying cause of their symptoms.

Breast cancers can be detected by the presence of the tumour marker CA 15-3.

Understanding Tumour Markers

Tumour markers are substances that can be found in the blood, urine, or tissues of people with cancer. They are used to help diagnose and monitor cancer, as well as to determine the effectiveness of treatment. Tumour markers can be divided into different categories, including monoclonal antibodies against carbohydrate or glycoprotein tumour antigens, tumour antigens, enzymes, and hormones. However, it is important to note that tumour markers usually have a low specificity, meaning that they can also be present in people without cancer.

Monoclonal antibodies are a type of tumour marker that target specific carbohydrate or glycoprotein tumour antigens. Some examples of monoclonal antibodies and their associated cancers include CA 125 for ovarian cancer, CA 19-9 for pancreatic cancer, and CA 15-3 for breast cancer.

Tumour antigens are another type of tumour marker that are produced by cancer cells. Examples of tumour antigens and their associated cancers include prostate specific antigen (PSA) for prostatic carcinoma, alpha-feto protein (AFP) for hepatocellular carcinoma and teratoma, carcinoembryonic antigen (CEA) for colorectal cancer, S-100 for melanoma and schwannomas, and bombesin for small cell lung carcinoma, gastric cancer, and neuroblastoma.

Understanding tumour markers and their associations with different types of cancer can aid in the diagnosis and management of cancer. However, it is important to interpret tumour marker results in conjunction with other diagnostic tests and clinical findings.

The addition of progestogen to HRT has been found to increase the risk of breast cancer. However, this risk is dependent on the duration of treatment and decreases after discontinuing HRT. It is important to note that this increased risk doesn’t affect the likelihood of dying from breast cancer. HRT with oestrogen alone may have no or reduced risk of coronary heart disease, while combined HRT has little to no increase in the risk of CHD. It is worth noting that there is no HRT available that contains progestogen only. Although NICE doesn’t provide specific risk analysis for ovarian cancer in women taking HRT, a meta-analysis suggests an increased risk for both oestrogen-only and combined HRT preparations.

Adverse Effects of Hormone Replacement Therapy

Hormone replacement therapy (HRT) is a treatment that involves the use of a small dose of oestrogen, often combined with a progestogen, to alleviate menopausal symptoms. However, this treatment can have side-effects such as nausea, breast tenderness, fluid retention, and weight gain.

Moreover, there are potential complications associated with HRT. One of the most significant risks is an increased likelihood of breast cancer, particularly when a progestogen is added. The Women’s Health Initiative (WHI) study found that the relative risk of developing breast cancer was 1.26 after five years of HRT use. The risk of breast cancer is related to the duration of HRT use, and it begins to decline when the treatment is stopped. Additionally, HRT use can increase the risk of endometrial cancer, which can be reduced but not eliminated by adding a progestogen.

Another potential complication of HRT is an increased risk of venous thromboembolism (VTE), particularly when a progestogen is added. However, transdermal HRT doesn’t appear to increase the risk of VTE. Women who are at high risk for VTE should be referred to haematology before starting any HRT treatment, even transdermal. Finally, HRT use can increase the risk of stroke and ischaemic heart disease if taken more than ten years after menopause.

In conclusion, while HRT can be an effective treatment for menopausal symptoms, it is essential to be aware of the potential adverse effects and complications associated with this treatment. Women should discuss the risks and benefits of HRT with their healthcare provider before starting any treatment.

Diagnosing Menopause According to NICE NG23

According to NICE NG23 guidelines, menopause can be diagnosed without laboratory tests in otherwise healthy women aged over 45 years with menopausal symptoms. Perimenopause can be diagnosed based on vasomotor symptoms and irregular periods, while menopause can be diagnosed in women who have not had a period for at least 12 months and are not using hormonal contraception. Menopause can also be diagnosed based on symptoms in women without a uterus.

However, in women aged 40 to 45 years with menopausal symptoms, including a change in their menstrual cycle, and in women aged under 40 years in whom menopause is suspected, a FSH test may be considered to diagnose menopause.

In the case of a woman aged over 45 years with amenorrhoea for over 12 months, a clinical diagnosis of menopause can be made without the need for blood tests. It is important to note that premature ovarian failure is not a concern in this case as the woman is aged 48.

Management of Endometriosis-Related Pain and Pelvic Inflammatory Disease

When it comes to managing endometriosis-related pain, a trial of paracetamol or an NSAID (alone or in combination) is recommended as first-line treatment. If this proves ineffective, other forms of pain management, including neuropathic pain treatment, should be considered. Hormonal treatment, such as COCP and POP, is also a sensible first-line option for women with suspected or confirmed endometriosis.

For pelvic inflammatory disease (PID), metronidazole + ofloxacin is often used as first-line treatment. However, there is no indication of this from the patient’s history. Referral to gynaecology would not add much at this stage, as they would likely offer the same options. Additionally, the patient is not keen on any surgical intervention at this point, which would include laparoscopy.

It’s important to note that GnRH agonists are not routinely started in primary care. They are sometimes started by gynaecology as an adjunct to surgery for deep endometriosis. Overall, a tailored approach to management is necessary for both endometriosis-related pain and PID, taking into account the individual patient’s needs and preferences.

Surgical Referral for Faecal and Urinary Incontinence

NICE guidelines recommend surgical referral for patients with faecal incontinence. Female patients with urinary incontinence should be referred to a urological expert with specific training and experience in treating stress incontinence. Surgical techniques for stress incontinence include mid-urethral tape and mesh suspension procedures, slings, intramural bulking agents, and traditional repair techniques. Other reasons for surgical referral include persistent bladder or urethral pain, pelvic masses, neurological disease, previous pelvic cancer surgery, and previous pelvic irradiation. It is important for healthcare professionals to be aware of these guidelines and refer patients appropriately for surgical intervention.

Bacterial vaginosis (BV) is a condition where there is an overgrowth of anaerobic organisms, particularly Gardnerella vaginalis, in the vagina. This leads to a decrease in the amount of lactobacilli, which produce lactic acid, resulting in an increase in vaginal pH. BV is not a sexually transmitted infection, but it is commonly seen in sexually active women. Symptoms include a fishy-smelling vaginal discharge, although some women may not experience any symptoms at all. Diagnosis is made using Amsel’s criteria, which includes the presence of thin, white discharge, clue cells on microscopy, a vaginal pH greater than 4.5, and a positive whiff test. Treatment involves oral metronidazole for 5-7 days, with a cure rate of 70-80%. However, relapse rates are high, with over 50% of women experiencing a recurrence within 3 months. Topical metronidazole or clindamycin may be used as alternatives.

Bacterial vaginosis during pregnancy can increase the risk of preterm labor, low birth weight, chorioamnionitis, and late miscarriage. It was previously recommended to avoid oral metronidazole in the first trimester and use topical clindamycin instead. However, recent guidelines suggest that oral metronidazole can be used throughout pregnancy. The British National Formulary (BNF) still advises against using high-dose metronidazole regimens. Clue cells, which are vaginal epithelial cells covered with bacteria, can be seen on microscopy in women with BV.

For women over 40, combined hormonal contraception (COCP) can be beneficial in reducing menstrual bleeding and pain, as well as alleviating menopausal symptoms. However, it is important to consider certain factors when prescribing COCP to women over 40. The UKMEC criteria for women over 40 is 2, while for women from menarche until 40, it is 1. The Faculty of Sexual and Reproductive Health recommends the use of COCP until age 50, provided there are no other contraindications. However, women over 50 should be advised to switch to a safer alternative method of contraception, as the risks associated with COCP use outweigh the benefits. Women who smoke should stop using COCP at 35, as smoking increases the risk of mortality. While COCP is associated with a reduced risk of ovarian and endometrial cancer, there is a slightly increased risk of breast cancer among women using COCP, which diminishes after 10 years of cessation. Women using COCP for non-contraceptive benefits after the age of 50 should be considered on an individual basis using clinical judgement and informed choice.

Women over the age of 40 still require effective contraception until they reach menopause, despite a significant decline in fertility. The Faculty of Sexual and Reproductive Healthcare (FSRH) has produced specific guidance for this age group, titled Contraception for Women Aged Over 40 Years. No method of contraception is contraindicated by age alone, with all methods being UKMEC1 except for the combined oral contraceptive pill (UKMEC2 for women >= 40 years) and Depo-Provera (UKMEC2 for women > 45 years). The FSRH guidance provides specific considerations for each method, such as the use of COCP in the perimenopausal period to maintain bone mineral density and reduce menopausal symptoms. Depo-Provera use is associated with a small loss in bone mineral density, which is usually recovered after discontinuation. The FSRH also provides a table detailing how different methods may be stopped based on age and amenorrhea status. Hormone replacement therapy cannot be relied upon for contraception, and a separate method is needed. The FSRH advises that the POP may be used in conjunction with HRT as long as the HRT has a progestogen component, while the IUS is licensed to provide the progestogen component of HRT.

Special Situations for Combined Oral Contraceptive Pill

Concurrent Antibiotic Use:
In the UK, doctors have previously advised that taking antibiotics concurrently with the combined oral contraceptive pill may interfere with the enterohepatic circulation of oestrogen, making the pill ineffective. As a result, extra precautions were advised during antibiotic treatment and for seven days afterwards. However, this approach is not taken in the US or most of mainland Europe. In 2011, the Faculty of Sexual & Reproductive Healthcare updated their guidelines, abandoning the previous approach. The latest edition of the British National Formulary (BNF) has also been updated in line with this guidance. Precautions should still be taken with enzyme-inducing antibiotics such as rifampicin.

Switching Combined Oral Contraceptive Pills:
The BNF and Faculty of Sexual & Reproductive Healthcare (FSRH) appear to give contradictory advice on switching combined oral contraceptive pills. The Clinical Effectiveness Unit of the FSRH has stated in the Combined Oral Contraception guidelines that the pill-free interval doesn’t need to be omitted. However, the BNF advises missing the pill-free interval if the progesterone changes. Given the uncertainty, it is best to follow the BNF.

Mirena® License for Contraception and Endometrial Hyperplasia Protection

At the moment, question stats are not available, but it is likely that many people will choose 5 years as the answer for Mirena®’s duration of use for contraception. However, it is important to note that while Mirena® is licensed for up to 5 years for contraception and idiopathic menorrhagia, it is only licensed for 4 years for protection against endometrial hyperplasia during oestrogen replacement therapy. This means that individuals using Mirena® for this purpose should have it replaced after 4 years to ensure continued protection. It is crucial to follow the recommended duration of use for Mirena® to ensure its effectiveness and safety.

Mild cases of pelvic inflammatory disease do not require removal of intrauterine contraceptive devices.

Pelvic inflammatory disease (PID) is a condition where the female pelvic organs, including the uterus, fallopian tubes, ovaries, and surrounding peritoneum, become infected and inflamed. It is typically caused by an infection that spreads from the endocervix. The most common causative organism is Chlamydia trachomatis, followed by Neisseria gonorrhoeae, Mycoplasma genitalium, and Mycoplasma hominis. Symptoms of PID include lower abdominal pain, fever, dyspareunia, dysuria, menstrual irregularities, vaginal or cervical discharge, and cervical excitation.

To diagnose PID, a pregnancy test should be done to rule out an ectopic pregnancy, and a high vaginal swab should be taken to screen for Chlamydia and Gonorrhoea. However, these tests may often be negative, so consensus guidelines recommend having a low threshold for treatment due to the potential complications of untreated PID. Management typically involves oral ofloxacin and oral metronidazole or intramuscular ceftriaxone, oral doxycycline, and oral metronidazole. In mild cases of PID, intrauterine contraceptive devices may be left in, but the evidence is limited, and removal of the IUD may be associated with better short-term clinical outcomes according to recent guidelines.

Complications of PID include perihepatitis (Fitz-Hugh Curtis Syndrome), which occurs in around 10% of cases and is characterized by right upper quadrant pain that may be confused with cholecystitis, infertility (with a risk as high as 10-20% after a single episode), chronic pelvic pain, and ectopic pregnancy.

The recommended duration for using Mirena as the progestogen component of HRT is 4 years, according to the British National Formulary and NICE guidelines. However, for contraception purposes, the license allows for use up to 5 years.

For women using the levonorgestrel-releasing intrauterine device solely for contraception or heavy menstrual bleeding, it can be retained for a longer period. If the patient is 45 years or older and no longer menstruating, the device can be kept until menopause (confirmed by FSH testing), even if it exceeds the recommended duration (off-label use).

If the patient is still menstruating, the levonorgestrel intrauterine device can be left in place for up to 7 years (off-label use) if the bleeding pattern is satisfactory.

New intrauterine contraceptive devices include the Jaydess® IUS and Kyleena® IUS. The Jaydess® IUS is licensed for 3 years and has a smaller frame, narrower inserter tube, and less levonorgestrel than the Mirena® coil. The Kyleena® IUS has 19.5mg LNG, is smaller than the Mirena®, and is licensed for 5 years. Both result in lower serum levels of LNG, but the rate of amenorrhoea is less with Kyleena® compared to Mirena®.